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Aims Uncertainty exists over the importance of device-detected short-duration atrial arrhythmias. Continuous atrial diag-
nostics, through home monitoring (HM) technology (BIOTRONIK, Berlin, Germany), provides a unique opportunity
to assess frequency and quantity of atrial ﬁbrillation (AF) episodes deﬁned as atrial high-rate events (AHRE).
Methods
and results
Prospective data from 560 heart failure (HF) patients (age 67+10 years, median ejection fraction 27%) patients with
a cardiac resynchronization therapy (CRT) device capable of HM from two multi-centre studies were analysed. Atrial
high-rate events burden was deﬁned as the duration of mode switch in a 24-h period with atrial rates of .180 beats
for at least 1% or total of 14 min per day. The primary endpoint was incidence of a thromboembolic (TE) event.
Secondary endpoints were cardiovascular death, hospitalization because of AF, or worsening HF. Over a median
370-day follow-up AHRE occurred in 40% of patients with 11 (2%) patients developing TE complications and mor-
tality rate of 4.3% (24 deaths, 16 with cardiovascular aetiology). Compared with patients without detected AHRE,
patients with detected AHRE.3.8 h over a day were nine times more likely to develop TE complications
(P ¼ 0.006). The majority of patients (73%) did not show a temporal association with the detected atrial episode
and their adverse event, with a mean interval of 46.7+71.9 days (range 0–194) before the TE complication.
Conclusion In a high-risk cohort of HF patients, device-detected atrial arrhythmias are associated with an increased incidence of
TE events. A cut-off point of 3.8 h over 24 h was associated with signiﬁcant increase in the event rate. Routine assess-
ment of AHRE should be considered with other data when assessing stroke risk and considering anti-coagulation
initiation and should also prompt the optimization of cardioprotective HF therapy in CRT patients.
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The morbidity and mortality of atrial fibrillation (AF) have a major
impact on health-care expenditure, largely as a consequence of
thromboembolic (TE) complications.
1
A signiﬁcant proportion of AF is asymptomatic but carries impor-
tant prognostic implications, as emphasized in the AFFIRM study.
2
Patients with undetected, ‘unprotected’ paroxysms of AF remain
at a continued risk of TE. Conventional detection methods, such
as Holter monitoring, are ineffective at detecting asymptomatic par-
oxysmal atrial ﬁbrillation (PAF).
3 Although data monitoring of
modern implantable pacemakers has enhanced diagnostic capa-
bility,
4 recognition of relevant data generally remains unchecked
until the scheduled device review with consequent delay in thera-
peutic intervention. Implantable devices with remote monitoring
offer a solution to this problem. Continuous atrial diagnostic data
provide a unique opportunity to assess the frequency and quantity
of AF episodes deﬁned as atrial high-rate events (AHRE). The
home monitoring (HM) technology (BIOTRONIK, Berlin,
Germany), provides both daily and instantaneous transmission on
event detection. This does not require patient involvement, is vali-
dated, and is a safe and reliable automatic remote system.
5
However, interpretation of the comprehensive data provided by
these devices increasingly falls outside of conventional guidelines.
There are limited data available as to what level of atrial high-rate
burden is clinically relevant and when thromboprophylaxis should
be employed.
Therefore, we proceeded to evaluate the clinical impact of high
atrial arrhythmic burden in a heart failure (HF) population receiving
cardiac resynchronization therapy (CRT) with remote monitoring
technology. Data were pooled from two international prospective
multi-centre studies.
Methods
Patient population
Data were considered from all patients enrolled in the international
prospective multi-centre observational Home CARE (clinicaltrials.gov
code NCT00376116) and everesT trials (Evaluation of the new Biotro-
nik Resynchronization+ICD System) (Appendix 1). All patients had HF
and a CRT device capable of continuous heart rhythm monitoring via
HM. Patients in sinus rhythm (including patients with a prior history of
AF) with .70% HM transmissions in the follow-up period and .3
months of HM follow-up were included in the evaluation. All trials
complied with the Declaration of Helsinki and were approved by the
locally appointed ethics committee of each participating centre.
Informed consent had been obtained from all the patients.
Device and Home Monitoring characteristics
Patients had received CRT devices with or without a deﬁbrillator
(Stratos LV-T, Kronos LV-T, or Lumax HF-T from BIOTRONIK)
with HM turned on. This wireless, mobile remote monitoring system
continuously records details of relevant clinical events (e.g. rhythm dis-
turbances and delivered therapies). However, as this was an observa-
tional study, no interventions were undertaken when high atrial
arrhythmia burden was detected. Also for the purposes of study analy-
sis we were unable to verify the detected atrial arrhythmias with the
available intracardiac electrograms (IEGM Online HD
w).
Detection of atrial burden
We deﬁned AHRE as the duration of mode-switch in a 24 h period.
Mode-switching in Stratos and Kronos devices occurs when ﬁve of
eight consecutive atrial beats are .180 bpm and continues until ﬁve
of eight are below 180. In Lumax devices the criteria for onset are
36 out of 48 atrial cycles with a rate .180 bpm and termination
occurs when 20 out of 24 atrial beats are at a slower rate than a pro-
grammed value. Prior studies using similar detection algorithms have
shown .95% sensitivity and speciﬁcity for the detection of atrial
tachycardia/atrial ﬁbrillation (AT/AF) episodes and measurements of
AT/AF burden.
6 Patients were included in the analysis if the total
detected AHRE burden in a 24 h period exceeded an accumulative
total of 14 min. This 14 min limit is due to the deﬁnition of AF
burden in the HM system in per cent per day. So 1% (¼ 14.4 min)
is the minimal amount detected per day.
Outcome events
The primary study endpoint was the incidence of (TE) event, including
stroke, transient ischaemic attack (TIA), and peripheral arterial embo-
lism (PAE). The secondary endpoints were cardiovascular death, hos-
pitalization because of AF, or worsening of HF. Ischaemic stroke was
deﬁned as an acute onset neurological deﬁcit due to focal cerebrovas-
cular inhibition of ﬂow, persisting for .24 h.
Data analysis
Baseline demographic characteristics were collated including individual
CHADS2 score.
7 The patients analysed in this study were divided into
the following groups: (Figure 1):
- Group 1A. Sinus rhythm at enrollment, no prior history of AF but
HM detected AHRE over the follow-up period.
- Group 1B. Sinus rhythm at enrollment and no prior history of AF
with no detected AHRE.
- Group 2A. Prior history of AF with detected AHRE over the
follow-up period.
- Group 2B. Prior history of AF with no detected AHRE over the
follow-up period.
Patients were included in Group 1A or 2A, if they experienced ≥1
AHRE event during the follow-up period. A prior history of AF was
deﬁned as attacks of AF lasting from 2 min to ,7 days (PAF) or AF
.7 days but ,1 year (persistent AF).
8 A diagnosis of prior AF
required documentation by EKG or Holter monitoring. All patients
were in SR at enrollment.
Figure 1 Study ﬂow chart. AHRE, atrial high rate events; SR,
sinus rhythm.
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Normally distributed continuous variables were calculated using mean
and standard deviation. Categorical data are presented as number and
percentage. Distributions were tested for normality using Shapiro2
Wilkinson statistics. Non-normally distributed variables were rep-
resented as median with 25th–75th interquartile range (IQR).
Comparison of normally distributed continuous variables was per-
formed using Student’s t-test for paired and unpaired data. Non-
normally distributed variables were compared using Mann–Whitney
Rank Sum tests and Kruskal–Wallis tests. Comparison of categorical
data was performed using x
2 and Fisher’s Exact tests where appropri-
ate. A global P value was calculated when comparing all four groups.
Statistical signiﬁcance was established as P , 0.05.
Differences in event rates over time were analysed by the Kaplan–
Meier analysis with Gehan–Breslow test for each outcome in the four
study groups. Multiple comparisons for the four different groups were
performed with the Holm–Sidak method. The Cox regression model
was used to analyse the effect of daily AHRE on TE and other compo-
site endpoints [(TE/cardiovascular death) and (AF and HF admissions/
TE/cardiovascular death)]. Thereby, the categorization of no AF, daily
AHRE. median (3.8 h), and daily AHRE ≥ median was used. SPSS
software (version 16 statistical package, SPSS Inc., Chicago, IL, USA)
was used for all the statistical analyses.
Results
Study population
Between August 2004 to August 2008, 936 HF/CRT patients were
enrolled from 77 European cardiac centres in the two trials. Of the
376 patients excluded from analysis, pre-enrollment AF status was
missing in 87 (9%) patients, 75 (8%) had ,70% HM data available
for analysis, 56 (6%) had ,90 days surveillance via HM, and 158
(17%) dropped out of the study. Analysis was undertaken on pro-
spective data from 560 patients, over a median follow-up period of
370 days (IQR from 253 to 390 days). See Table 1 for study popu-
lation demographics.
All four groups had similar baseline characteristic, although
there were signiﬁcantly more patients with ischaemic HF in
Group 1A compared with the other three groups. Accordingly,
the uptake of cardioprotective medication including beta-blockers,
...............................................................................................................................................................................
Table 1 Patient Characteristics for all 560 patients including subgroup demographics
Variable baseline
patient characteristics
Total study
population
AHRE Group
1A
No AHRE
Group 1B
Prior history of AF
pre entry
Prior history of AF
pre entry
Global
P value
(n 5 560) (n 5 126) (n 5 256) Group 2A AHRE Group 2B no
AHRE
(n 5 97 (n 5 81)
Male 434 (77.4%) 107 (84.9%) 189 (73.8%) 73 (75.3%) 65 (80.2%) 0.086
Age (years) 66 + 10 65 + 10 67 + 10 68 + 10 69 + 9 0.07
QRS (ms) 160 (140–178) 165 (140–180) 160 (132–173) 160 (140–180) 160 (140–173) 0.14
Non-ischaemic 258 (46.1%) 48 (38.1%) 126 (49.2%) 46 (47.4%) 38 (46.1%) 0.23
NYHA I 7 (1.25%) 1 (0.8%) 4 (1.6%) 0 (0%) 2 (2.5%)
NYHA II 108 (19.3%) 24 (19.0%) 51 (19.9%) 17 (17.5%) 16 (19.8%) 0.81
NYHA III 401 (71.6%) 94 (74.6% 178 (69.5%) 74 (76.3%) 55 (67.9%)
NYHA IV 36 (6.43%) 5 (4.0%) 19 (7.4%) 6 (6.2%) 6 (7.4%)
EF (%) 25 (20–30) 27 (20–30) 25 (20–30) 28 (20–32) 25 (20–28) 0.14
Diabetes 179 (32%) 37 (29.4%) 82 (32.0%) 31 (32%) 29 (35.8%) 0.82
Hypertension 210 (37.5%) 45 (35.7%) 95 (37.1%) 35 (36.1%) 35 (43.2%) 0.71
Pre-implant Stroke 1 (0.18%) 1 (0.79%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0.33
CHADS2 Score 1 202 (36.1%) 49 (38.9%) 95 (37.1%) 34 (35.1%) 24 (29.6%)
CHADS2 Score 2 216 (38.6%) 48 (38.1%) 95 (37.1%) 36 (37.1%) 37 (45.7%) 0.47
CHADS2 Score 3 128 (22.9%) 29 (23.0%) 56 (21.9%) 24 (24.7%) 19 (23.5%)
CHADS2 Score 4 14 (2.5%) 0 (0.0%) 10 (3.9%) 3 (3.1%) 1 (1.2%)
ACEI 354 (63.2%) 89 (70.6%) 165 (64.5%) 55 (56.7%) 45 (55.6%) 0.07
Beta-blockers 353 (63%) 91 (72.2%) 166 (64.8)% 50 (51.5%) 46 (56.8%) 0.008
Amiodarone 103 (18.4%) 17 (13.5%) 36 (14.1%) 22 (22.7%) 28 (34.6%) 0.0001
Other anti-arrythmics 110 (19.6%) 18 (14.3%) 38 (14.8%) 24 (24.7%) 30 (37.0%) 0.0004
Anti-platelets 239 (42.7%) 64 (50.8%) 119 (46.5%) 28 (28.9%) 28 (34.6%) 0.002
Warfarin 67 (12.0%) 9 (7.14%) 22 (8.59%) 19 (19.6%) 17 (21.0%) 0.0007
CRT (%) bivent pacing 98 (95–99) 98 (95–99) 98 (95–99) 98 (95–99) 99 (95–99) 0.07
HM performance% 93 (87–97) 94 (89–97) 93 (87–97) 92 (84–96) 94 (86–97) 0.31
Data are presented as the mean value+SD or median value (25th–75th percentile) for continuous variables and number and percentage of patients for categorical data.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AHRE, atrial high-rate events; BiV biventricular pacing; EF, ejection fraction; HM, Home
Monitoring; NYHA, New York Heart Association; other anti-arrythmics include Sotolol and Class 1 anti-arrythmics.
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tor blocker (ARBs) and anti-platelets was increased in this group.
Anticoagulation use among patients with known prior AF
(Group 2A 19.6% and Group 2B 21%) was signiﬁcantly higher
than in Group 1A (7%) or Group 1B (8%). The zero atrial
burden noted in Group 2B may have been explained by the signiﬁ-
cantly increased usage of anti-arrhythmic medication, including
amiodarone, observed in this group. Of further relevance to our
CRT cohort, the median frequency of biventricular pacing over
the total follow-up period was .98% (IQR 95–99) for all four
groups.
Quantiﬁcation of atrial tachyarrhythmic
burden
At least, 40% of the study population had at least 1 day where they
had atrial tachyarrhythmias totalling .14 min (1% of day). Further-
more, in the sinus rhythm group with no prior history of AF, the
annual incidence of a device detected atrial episode was 33%.
Despite the prior history of AF only 64% of patients in Group 2
demonstrated a monitored atrial event. However, the median
daily AHRE was substantially greater in Group 2A (647 min IQR
84–700) compared with Group 1A (44 min IQR 11–179; P ¼
0.0001).
Clinical events
See Table 2, for summary of clinical event rates in all four groups.
Arterial thromboembolic complications
Over a median follow-up period of 370 days TE complications
occurred in 11 patients (2.0%). In particular, ﬁve patients suffered
a PAE, four ischaemic strokes, and two TIA. There were no associ-
ated TE events in those patients with no prior history of AF and
zero atrial burden over the follow-up period. However, two PAE
events (18.1%) did occur in Group 2B. Consequently, if a patient
developed new atrial episodes or had a prior history of AF, they
were more likely to develop a TE complication compared with
patients in Group 1B. Furthermore, there was no statistical differ-
ence in the cumulative probability of developing a TE complication
between Group 1A and 2A (P ¼ 0.124). Despite there being no
detected atrial arrhythmia in Group 2B, the TE outcomes were
similar to those patients experiencing AHRE (Group 2B vs. 1A
P ¼ 0.15 and Group 2B vs. Group 2A, P ¼ 0.5) (Figure 2).
Mortality
There were 24 (4.3%) deaths in total, with 16 (67%) due to a car-
diovascular aetiology. There was no difference in all-cause mor-
tality between the four study groups.
Heart failure admissions
A total of 52 (9.3%) admissions for HF were observed in the study
population. Patients with a prior history of AF, whether or not they
experienced a period of atrial burden, were more likely to be
admitted with decompensated HF [7.9% (Group 1A), 5.1%
(Group 1B) vs. 16.5% in Group 2A and 16% in Group 2B; P ¼
0.001] (Figure 3).
The temporal association between atrial
arrhythmias and clinical events
Arterial thromboembolic complications
The last detected episode of AHRE was 46.7+71.9 days (range
0–194) before the TE event. Of those with detected atrial
burden, who suffered a TE complication, three (27.3%) were
in an atrial arrhythmia at the time of diagnosis. Interestingly,
four patients (36.4%) who developed TE events had no
prior atrial arrhythmia recorded, including two patients from
Group 2B.
Heart failure admissions
AsforTEcomplications,therewasasimilarperiodofdelaybetween
the admission for HF and the detected atrial event (mean 47.4+
88.6 days, range 0–339). Moreover, 63.5% (n ¼ 33/52) of patients
had no atrial trigger recorded prior to their admission. Only seven
(13.4%) patients were in an AHRE at the time of admission.
An atrial burden cut-off
Based on published analytical strategy,
9 a cut-off was deﬁned
before data analysis as the observed median value of daily AHRE
burden. Among those with detected AHRE the median value
was 16% per day or 3.8 h and the study population was divided
into three subsets: zero AHRE, low AHRE burden if below the
median and high AHRE burden if above.
After adjusting for TE risk factors, Cox multivariate analysis
demonstrated that a maximum AHRE longer than the median
3.8 h over a 24 h period was independently associated with TE
events compared with patients with zero AHRE (HR 9.4; CI
1.8–47.0 P ¼ 0.006). However, when comparing patients with a
high AHRE burden (≥3.8 h) to those with a low burden
...............................................................................................................................................................................
Table 2 Adverse event rates for all four study groups
Clinical event Total events Group 1A Group 1B Group 2A Group 2B Global P value
n 5 126 n 5 256 n 5 97 n 5 81
TE 11 (2.0%) 5 (4.0%) 0 (0%) 4 (4.1%) 2 (2.5%) 0.02
All-cause mortality 24 (4.3%) 7 (5.6%) 8 (3.1%) 4 (4.1%) 5 (6.2%) 0.56
CVS mortality 16 (2.9%) 4 (3.2%) 4 (1.6%) 4 (4.1%) 4 (4.9%) 0.33
HF admission 52 (9.3%) 10 (7.9%) 13 (5.1%) 16 (16.5%) 13 (16%) 0.001
Data are presented as number and percentage.
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event or cardiovascular death was highly predictive for an AHRE
burden cut-off of 3.8 h (HR 3.9 CI 1.9–7.9, P , 0.0001). (Table 3).
Discussion
Using data from two international multi-centre studies, this study
has shown that the detection of atrial events by remote device
monitoring is associated with TE complications in sinus rhythm
patients with HF and CRT; moreover, they also have a similar TE
event rate to those patients with a prior history of AF.
Compared with patients with no detected AHRE, patients with
device-detected AHRE burden .3.8 h in 1 day were nine times
more likely to develop TE complications and four times more
likely to die from a cardiovascular cause.
In addition, those patients with 3.8 h or more of AHRE were at
signiﬁcantly higher risk of being admitted with AF or decompen-
sated HF, to develop a TE complication or die from a cardiac
cause when compared with patients with an AHRE burden
,3.8 h. Interestingly, the majority of patients (73%) did not
show a temporal association with the detected atrial episode and
their adverse event, with a mean lag period of 46.7+71.9 days
before the TE complication.
Atrial burden studies to date
In the few studies that have assessed the clinical impact of device-
detected AHRE
9–16 only three have been in patients with HF and
CRT, although none assessed the impact on TE event rates.
10–12
Two of the studies relied on routine device interrogation.
10,11 In a
retrospective analysis of their single-centre experience of 161
patients with CRT devices, Caldwell et al. did not demonstrate sig-
niﬁcant difference in outcomes between patients in sinus rhythm
or newly detected PAF.
10 In a subsequent study by Borleff et al.
11
there was a signiﬁcant difference in outcomes between the AHRE
group and the sinus rhythm group, using a composite endpoint of
all cardiac hospitalizations and (appropriate or inappropriate)
shock therapy.
However, Santini et al.
12 have recently demonstrated similar
adverse outcome data to our study with the use of continuous
device diagnostics in 1193 patients in sinus rhythm with CRT.
They clearly showed a higher incidence of the composite endpoint
of death and HF hospitalizations among patients with AT/AF during
follow-up when compared with patients without AT/AF. However,
no data were reported on the TE event rates.
The Mode Selection Trial (MOST) substudy
13 showed that
almost 50% of patients with bradycardia pacing devices and
sinus node disease had at least one atrial high-rate event lasting
a minimum of 5 min, and this was an independent predictor for
the combined endpoint of death or non-fatal stroke. Sub-
sequently, Glotzer et al.
9 attempted to deﬁne a threshold for
stroke risk in device-detected AF. They demonstrated that
patients, with moderate stroke-risk factors, evidence of atrial
arrhythmias .5.5 h/day in a 30-day period had a TE event rate
of 2.4% per year. Although the hazard ratio of 2.2 suggested
that this cut-off doubled the risk of TE event compared to the
low-burden group, the conﬁdence intervals were wide (0.96–
5.05). Capucci et al.
14 reported that patients with bradycardia
pacing indications and atrial events .24 h were three times
more likely, after adjustment for risk factors, to have TE compli-
cations than those who had atrial arrhythmias ,24 h. Similarly, in
the recent ASSERT Trial (Asymptomatic AF and Stroke
No AHRE
Prior history AF-No AHRE
Group 1B
Group 2B
Prior history AF-AHRE Group 2A
AHRE
Gehan-Breslow p=0.027
Group 1A
0
0.7
0.8
0.9
1.0
200 400 600
Time (days)
Comparisons
of Groups
Critical
Level
Statistic P Value
1B vs. 2A
1A vs. 1B
1B vs. 2B
2A vs. 2B
1A vs. 2B
1A vs. 2A
0.0085
0.0102
0.013
0.017
0.025
0.05
0.0011
0.0044
0.016
0.46
0.70
0.73
10.6
8.11
5.83
0.54
0.153
0.125
800 1000
Figure 2 Kaplan2Meier cumulative survival from thromboem-
bolic (TE) events for all four groups of patients. Multiple compari-
sons of the groups by the Holm2Sidak method are presented.
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Figure 3 Kaplan2Meier cumulative survival from heart failure
(HF) admissions for all four groups of patients. Multiple compari-
sons of the groups by the Holm2Sidak method are presented.
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Trial), Healey et al. were able to demonstrate, in hypertensive
patients receiving a dual-chamber pacemaker with no prior
history of PAF, more than a doubling of embolic risk with the
presence of atrial arrhythmias.
15
Clinical relevance of device-detected
atrial burden
Although it is accepted that the stroke risk in PAF, persistent and
permanent AF
17 is similar, uncertainty exists over the importance
of short-duration atrial arrhythmias. While prothrombogenic elec-
trical remodelling of the human atria may occur with AF durations
.20 min
18 few would consider anti-coagulation at this level. Our
study supports the ﬁndings in the MOST study
14 suggesting that
device-detected atrial events of short duration may be as relevant
as having a clinical history of PAF. Certainly, our study shows that
the incidence of TE complications was similar in the group with a
pre-existing AF compared with the sinus rhythm group with newly
detected atrial arrhythmias.
However, the difﬁculty encountered for predicting a clinically
relevant AHRE burden threshold, is the low TE event rate in the
atrial burden studies. In a total of ﬁve atrial burden
studies
9,13,14,16 (including our data) totalling 4651 followed up
over a median period of 18 months, there were only 51 TE
events (1.1% incidence). This low event rate may be a consequence
of a short follow-up period or reﬂect under-reporting of embolic
events. Interestingly, in the relatively longer ASSERT study
15 (mean
3-year follow-up) the overall rate of the TE complications was
0.72% per year.
The presence of device-detected AHRE: is
it a surrogate marker of disease severity
Although, a causal link between the onset of AHRE and TE com-
plications can be inferred in (3 of 11) 27% of patients in our
study, the majority did not demonstrate a direct temporal link
with both TE complications and HF admissions. Our ﬁndings cor-
relate with the recently reported 40-patient subgroup analysis of
patients with TE complications from the TRENDS study. Daoud
et al.
19 were able to show that in their 40 patients, who demon-
strated atrial episodes prior to a TE event, 29 (73%) did not
have an atrial arrhythmia in the 30 days prior to a TE event; a
similar incidence as shown in our study. They go on to postulate
that there may be other mechanisms, such as vascular disease
risk factors, other than cardioembolism, which may come into
play. Others have suggested that patients with device-detected
atrial arrhythmias have more ‘severe underlying heart disease’
and hence higher mortality;
13 while it is also well known that the
development of AF is a marker of increased mortality in patients
with underlying heart disease.
20
Heart failure admissions
The signiﬁcantly increased admissions for decompensated HF
observed in Groups 1A and 2 compared with those with no
prior history of AF who remained in sinus rhythm throughout
the follow-up period (Group 1B) may be explained by Borleffs
et al.
11 observation that patients with newly detected AF
post-CRT-D, had less reverse LV remodelling and no improvement
in MR severity or LA size. Although our results do not demon-
strate a causal relationship between the development of AF and
worsening HF, our study highlights that in CRT HF patients the
device detection of AHRE may, in fact, represent a marker for
worsening HF or HF hospitalization. Furthermore, the excellent
biventricular pacing rate, observed in all four study groups,
would further reiterate that the presence of AHRE may represent
a marker of increased disease state. This would counter the ﬁnd-
ings shown by Santini et al.
12 who had linked the deterioration in
HF with the impact of reduced biventricular pacing, due to an over-
riding atrial rate.
The role of anti-coagulation for
device-detected atrial arrhythmias
Although our study does not deﬁne a level of atrial burden at
which anti-coagulation is required it does support prior studies
.........................................................................................................................
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Table 3 Results of hazard ratios comparing atrial high-rate events variables for each clinical outcome based on Cox
regression model
Clinical outcome AHRE variable
Low AHRE vs. zero AHRE High AHRE vs. zero AHRE High AHRE vs. low AHRE
TE HR 4.3 HR 9.4 HR 2.4
(CI 0.73–26.2) (CI 1.8–47.0) CI (0.58–9.8)
P ¼ 0.11 P ¼ 0.006 P ¼ 0.23
TE + cardiovascular death HR 2.1 HR 4.0 HR 2.0
(CI 0.72–6.0) (CI 1.5–10.1) (CI 0.73- 5.6)
P ¼ 0.17 P ¼ 0.004 P ¼ 0.18
TE + AF
a+ HF
b+ cardiovascular death HR 1.0 HR 3.8 HR 3.9
(CI 0.49–2.1) (CI 2.3–6.3) (CI 1.9–7.9)
P ¼ 1.0 P , 0.0001 P , 0.0001
Low AHRE corresponds to a burden of 14 min to ,3.8 h in 24 h monitoring period, high AHRE corresponds to a burden .3.8 h in a 24 h monitoring period.
aAF admissions.
bHeart failure admissions.
Detection of atrial high-rate events by continuous Home Monitoring 235in considering lower levels of atrial ﬁbrillation to be clinically signiﬁ-
cant.
9–15
Following an interesting study correlating stroke risk and device-
detected AHRE, Botto et al.,
16 recommended anti-coagulation if
patients developed 5 min or more of AF and had a CHADS2
score of .2. They also suggested that if patients experienced
24 h or more of AF despite a CHADS2 score of ,1, they also
should be considered for therapy. We eagerly await the results
of the ongoing interventional prospective multi-centre study of
remote monitoring of AF, which should provide the strongest evi-
dence for the role of anticoagulation.
21 In the worldwide survey,
Lazarus retrospectively analysed 3 million transmissions in over
11 000 patients with brady pacing, implantable cardioverter deﬁ-
brillator (ICD) and CRT-D devices. He reported that events
were detected 2–5 months earlier than allowed by standard
care and was associated with expedited anti-coagulation in 30%
of patients and modiﬁcation of anti-arrhythmic therapy in 42%.
22
Study limitations
The major limitations were that atrial events were not veriﬁed by
evaluating the electrograms and that two different AF burden-
detection methods were employed. Although, all atrial rates
,180 beats per minute were excluded to minimize the false-
positive detection of arrhythmias, patients were included if they
had an accumulative total of (1%) or 14 min of data detected
per day, which would allow shorter episodes (,5 min) to be
included and increase the chance of oversensing. Previously pub-
lished data suggest that excluding episodes ,5 min reduces the
chance of oversensing.
23 Also, the inclusion requirement of
.70% HM data transmission and the minimum of 90 days of
follow-up over the total study period may have contributed to
some patients having limited amount of data for analysis.
The low frequency of TE complications introduces room for
statistical error, especially when assessing for predictors of TE
events and obtaining an AHRE burden cut-off. Another limitation
is that we are unable to truly verify whether patients in Group 1
did in fact have previous asymptomatic AF. Furthermore, our
study was not designed to assess the clinical response to CRT
and this could have had an impact on the incidence of atrial
arrhythmia burden. However, in the larger randomized trials
CRT has not been shown to decrease the incidence of AF.
24,25
Conclusions
Remote monitoring of implantable cardiac devices is a feasible and
effective means of arrhythmia surveillance in HF patients. We have
demonstrated that atrial arrhythmias detected by implanted
devices are associated with an increased incidence of TE events,
with a cut-off point of 3.8 h being associated with a signiﬁcant
increase in event rate. Device-detected atrial episodes may also
represent a marker of disease severity or risk and hence the
routine assessment of AHRE data, in patients with HF, should be
considered with other diagnostic information when assessing
stroke risk and considering anti-coagulation initiation. Further-
more, it should also prompt the optimization of cardioprotective
HF therapy and arrhythmia management in CRT patients.
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Appendix 1
everesT Study
Evaluation of the new BIOTRONIK
Resynchronization 1 ICD System
Objective
The international multi-centre prospective study ‘everesT’ is
designed to evaluate safety and efﬁcacy of BIOTRONIK’s CRT-D
device: Lumax HF-T 300 and 340, and BIOTRONIK’s bipolar LV
lead: Corox OTW BP Steroid and Corox OTW-S BP Steroid.
This study documents ﬁrst clinical experience with the handling
and function of these products during the intra- and post-operative
course.
Patient selection
Inclusion criteria
† All the following criteria must be fulﬁlled to include the patient
in this study:
† Patient is willing and able to comply with the protocol and has
provided written informed consent.
† Indication for CRT
† Indication for implantation of an ICD
† Stable residence anticipated for 6 months after enrollment
Exclusion criteria
† The patient is not eligible to enter this study, if one of the below
listed exclusion criteria is fulﬁlled:
† Planned cardiac surgical procedures within 6 months after
enrollment
† Life expectancy ≤ 6 months
† Pregnant and breast-feeding women
† Age , 18 years or otherwise missing complete contractually
capability
† Participation in another clinical study
† For part A only: patient inclusion stopped by sponsor
† For part B only: Corox OTW(-S) BP not yet available on the
market.
N. Shanmugam et al. 236† For part B only: LV lead implanted or any failed attempt to
implant an LV lead prior to enrolment
Primary endpoints
(1) Safety and efﬁcacy of Lumax 300/340 HF-T - Part A
(2) Safety and efﬁcacy of Corox OTW(-S) BP - Part B
Secondary endpoints
(1) Observations and complications related to Lumax 300/340
HF-T (A)
(2) Rate of inappropriate ICD therapies (A)
(3) Shock impedance (A)
(4) VF detection time (A)
(5) Observations and complications related to Corox OTW(-S)
BP (B)
(6) Lead parameters (B)
(7) Patient deaths (A/B)
Publication
Results of the study have not been published yet. But the data
received and analysed during the everesT clinical study demon-
strated the safety and efﬁcacy of the Lumax HF-T CRT-D device
and Corox OTW(-S) BP Steroid LV leads and supported the
FDA approval of Corox BP lead.
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